UW Medicine endocrinologist draws line between approved and unregulated peptides
Bradley Anawalt contrasts decades-tested drugs such as insulin and GLP-1 agonists with BPC-157 and TB-500, which he notes have not been studied in humans.
PR
By Priya Raman · Science Reporter
Oct 7 08:00 ETSource: Right as Rain by UW Medicine
The wire
- 01UW Medicine explainer from endocrinologist Bradley Anawalt separates FDA-approved peptide drugs, including insulin from the 1920s and synthesized oxytocin marketed as Pitocin, from unregulated injectables sold for recovery and anti-aging.
- 02Clinicians fielding patient questions about BPC-157 and TB-500 get a citable framing: these compounds sit outside the approval pathway that GLP-1 agonists took over decades of animal and human testing.
- 03The piece offers no new data and does not address the FDA advisory panel activity around these compounds; it is a patient-education article, not a regulatory development.
From the source
Read at rightasrain.uwmedicine.orgPeptide Therapies Are Everywhere. What Are They Exactly?
Peptides seem to be everywhere these days, along with sweeping claims about improving recovery, slowing aging, increasing muscle and decreasing fat.
